Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125820812 | 12582081 | 2 | F | 20160520 | 20160808 | 20160722 | 20160810 | EXP | FR-ROCHE-1796719 | ROCHE | 80.00 | YR | F | Y | 0.00000 | 20160810 | MD | FR | FR |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125820812 | 12582081 | 1 | PS | MABTHERA | RITUXIMAB | 1 | Intravenous drip | LAST CYCLE OF CHEMOTHERAPY WAS ADMINISTRATED IN APR/2016.?8 CYCLES | 103705 | SOLUTION FOR INFUSION | |||||||||
125820812 | 12582081 | 2 | C | ADRIBLASTINE | DOXORUBICIN | 1 | Intravenous drip | LAST CYCLE OF CHEMOTHERAPY WAS ADMINISTRATED IN APR/2016.?8 CYCLES | 0 | ||||||||||
125820812 | 12582081 | 3 | C | ENDOXAN | CYCLOPHOSPHAMIDE | 1 | Intravenous drip | LAST CYCLE OF CHEMOTHERAPY WAS ADMINISTRATED IN APR/2016.?8 CYCLES | 0 | ||||||||||
125820812 | 12582081 | 4 | C | ONCOVIN | VINCRISTINE SULFATE | 1 | Intravenous drip | LAST CYCLE OF CHEMOTHERAPY WAS ADMINISTRATED IN APR/2016.?8 CYCLES | 0 | ||||||||||
125820812 | 12582081 | 5 | C | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | LAST CYCLE OF CHEMOTHERAPY WAS ADMINISTRATED IN APR/2016.?8 CYCLES | 0 | ||||||||||
125820812 | 12582081 | 6 | C | ZELITREX | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | 0 | 500 | MG | Q12H | ||||||||
125820812 | 12582081 | 7 | C | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 0 | TABLET | ||||||||||
125820812 | 12582081 | 8 | C | APIXABAN | APIXABAN | 1 | Unknown | 0 | 2.5 | MG | Q12H | ||||||||
125820812 | 12582081 | 9 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | Oral | 0 | 5 | MG | BID | ||||||||
125820812 | 12582081 | 10 | C | PARACETAMOL | ACETAMINOPHEN | 1 | Oral | 0 | 500 | MG | |||||||||
125820812 | 12582081 | 11 | C | MACROGOL | POLYETHYLENE GLYCOLS | 1 | Oral | 0 | 1 | DF | QD | ||||||||
125820812 | 12582081 | 12 | C | ESOMEPRAZOLE | ESOMEPRAZOLE | 1 | Oral | 0 | 40 | MG | QD | ||||||||
125820812 | 12582081 | 13 | C | STILNOX | ZOLPIDEM TARTRATE | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125820812 | 12582081 | 1 | Diffuse large B-cell lymphoma |
125820812 | 12582081 | 2 | Diffuse large B-cell lymphoma |
125820812 | 12582081 | 3 | Diffuse large B-cell lymphoma |
125820812 | 12582081 | 4 | Diffuse large B-cell lymphoma |
125820812 | 12582081 | 5 | Diffuse large B-cell lymphoma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125820812 | 12582081 | DE |
125820812 | 12582081 | LT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125820812 | 12582081 | Altered state of consciousness | |
125820812 | 12582081 | Asthenia | |
125820812 | 12582081 | Balance disorder | |
125820812 | 12582081 | Dysarthria | |
125820812 | 12582081 | Dysphagia | |
125820812 | 12582081 | General physical health deterioration | |
125820812 | 12582081 | Oral fungal infection | |
125820812 | 12582081 | Orthostatic hypotension | |
125820812 | 12582081 | Progressive multifocal leukoencephalopathy | |
125820812 | 12582081 | Psychomotor skills impaired |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125820812 | 12582081 | 1 | 201511 | 201604 | 0 | |
125820812 | 12582081 | 2 | 201511 | 201604 | 0 | |
125820812 | 12582081 | 3 | 201511 | 201604 | 0 | |
125820812 | 12582081 | 4 | 201511 | 201604 | 0 | |
125820812 | 12582081 | 5 | 201511 | 201604 | 0 |